ABPI responds to UK medicines cost controversy

Alison Clough, acting CEO of the Association of the British Pharmaceutical Industry (ABPI), has responded to recent reports in the media concerning the spiralling cost of medicines in the UK, and the premium it apparently pays when compared to other countries.

Coverage has claimed that UK-based patients are being denied access to some potentially life-extending cancer drugs as a result of companies charging higher prices for the same medications in Britain than in other countries.

Image caption: 

ABPI acting CEO, Alison Clough

read more http://www.pharmafile.com/news/499051/abpi-responds-uk-medicines-cost-controversy